Who
Kyle Carver
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Evommune; SVP, CAO, Controller, Kadmon Holdings.
In numbers
- Trades disclosed
- 23
- Buys
- 1
- Sells
- 1
- Bought
- $27K
- Sold
- $830K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 14 Dec 2018
- Last trade
- 8 Jul 2026
- Last filed
- 10 Jul 2026
Companies traded
Activity over time
1 May – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jul 2026filed 10 Jul 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Bought | $13K1,000 at $13.26 | filing |
| 8 Jul 2026filed 10 Jul 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Bought | $13K1,000 at $13.26 | filing |
| 28 May 2026filed 1 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Code M | $45K15,000 at $2.99 | filing |
| 28 May 2026filed 1 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Sold | $415K18,175 at $22.84 | filing |
| 28 May 2026filed 1 Jun 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Code M | $45K15,000 at $2.99 | filing |
| 28 May 2026filed 1 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Sold | $415K18,175 at $22.84 | filing |
| 16 Apr 2026filed 17 Apr 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —98,946 at $0.00 | filing |
| 16 Apr 2026filed 17 Apr 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —98,946 at $0.00 | filing |
| 9 Dec 2025filed 11 Dec 2025 | EVMN EvommuneBiotechnology | SEC FORM 4 Code F | $237K13,290 at $17.84 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —25,000 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN EvommuneBiotechnology | SEC FORM 4 Code C | —3,175 | filing |
| 5 Nov 2025filed 7 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —279,408 at $0.00 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $218K45,000 at $4.84 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $322K55,000 at $5.86 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $352K50,000 at $7.03 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $516K100,000 at $5.16 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $970K175,000 at $5.54 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdings | SEC FORM 4 Code D | $146K15,420 at $9.50 | filing |
News
Evommune (NYSE:EVMN) Stock Bumped Up to "Hold" by UBS GroupEVMN · tickerreport.com · 14 Oct 2026Evommune (NYSE:EVMN) Upgraded at UBS GroupEVMN · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Kyle Carver; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.